Advanced Search
Contact | Corporate | Help

Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

Sponsors:
  • Memorial Sloan-Kettering Cancer Center
  • Genentech
Phases:
IndicationsAcronym:
  • Sarcoma
  • Desmoplastic Small Round Cell Tumor (DSRCT)
Age Groups:
  • Child
  • Adult
Gender:
Both
Names:
  • Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
Enrollment:
15

Additional information about NCT01189643.


SourceSolution © 2008-2012